<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013359</url>
  </required_header>
  <id_info>
    <org_study_id>DAS-003</org_study_id>
    <secondary_id>U1111-1262-1190</secondary_id>
    <nct_id>NCT05013359</nct_id>
  </id_info>
  <brief_title>Awareness, Care &amp; Treatment In Obesity Management - An International Observation Among Teens (ACTION Teens)</brief_title>
  <acronym>ACTION Teens</acronym>
  <official_title>Awareness, Care &amp; Treatment In Obesity Management - An International Observation Among Teens (ACTION Teens)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACTION Teens is a multinational cross-sectional survey-based study. The study consists of a&#xD;
      quantitative online survey to be conducted among three groups of respondents in ten countries&#xD;
      worldwide. The respondent population will include Adolescents Living with Obesity (ALwO),&#xD;
      Caregivers of ALwO, and HCPs treating adolescents who have obesity.&#xD;
&#xD;
      The goal of this study is to provide insights to drive awareness around the needs of&#xD;
      adolescents living with obesity and their caregivers, as well as to identify key areas of&#xD;
      misalignment between adolescents, their caregivers and the HCPs involved in obesity treatment&#xD;
      and management. ACTION Teens is designed to generate evidence to identify and address these&#xD;
      challenges on both a global and local level, extending the insights from the previously&#xD;
      conducted ACTION-IO study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 21, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Attitudes about obesity, attitudes about people with obesity, and beliefs about the impact of obesity</measure>
    <time_frame>At the time of survey response (Day 1)</time_frame>
    <description>5-point Likert scales (e.g., agreement, impact, frequency)&#xD;
- Proportion of responses in each category will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight loss attempts in past year, motivations to lose weight, barriers to losing weight, and definition of successful weight loss/management</measure>
    <time_frame>At the time of survey response (Day 1)</time_frame>
    <description>Yes/No; percentage of participants&#xD;
Multi-select from defined list&#xD;
- Percentage of respondents selecting an item or items will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>History and frequency of conversations about weight, initiator of weight conversations, and responsibility for initiating weight conversations that occur between adolescents living with obesity/their caregivers and healthcare providers</measure>
    <time_frame>At the time of survey response (Day 1)</time_frame>
    <description>Numeric entry; percentage of participants Single select from defined list; percentage of time each initiates Single select from defined list</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of interactions between adolescents living with obesity/their caregivers and healthcare providers, reasons why obesity may not be discussed, frequency of obesity diagnosis, and frequency of follow-up appointments made to discuss obesity</measure>
    <time_frame>At the time of survey response (Day 1)</time_frame>
    <description>5-point Likert scales Multi-select from defined list Yes/No; percentage of patients Yes/No; percentage of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sources of information used to learn about obesity, healthy lifestyles, weight loss, and weight management</measure>
    <time_frame>At the time of survey response (Day 1)</time_frame>
    <description>Multi-select from defined list</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">14600</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Adolescents Living with Obesity (ALwO)</arm_group_label>
    <description>Recruited from online, general population consumer panels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Care Providers (HCPs)</arm_group_label>
    <description>HCPs treating adolescents who have obesity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caregivers</arm_group_label>
    <description>A parent or legal guardian of an adolescent with obesity</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>No treatment given</description>
    <arm_group_label>Adolescents Living with Obesity (ALwO)</arm_group_label>
    <arm_group_label>Caregivers</arm_group_label>
    <arm_group_label>Health Care Providers (HCPs)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The respondent population will include Adolescents living with obesity (ALwO), Caregivers&#xD;
        of ALwO, and HCPs treating adolescents who have obesity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Adolescents living with obesity:&#xD;
&#xD;
          -  Informed consent obtained by parent/legal guardian and ALwO before any study-related&#xD;
             activities (study-related activities are any procedure related to recording of data&#xD;
             according to the protocol).&#xD;
&#xD;
          -  Male or female, aged 12 to less than 18 years at the time of signing informed consent.&#xD;
&#xD;
          -  Lives in one of the participating countries: Italy, Spain, UK, Mexico, Colombia,&#xD;
             Australia, Saudi Arabia, Turkey, South Korea, and Taiwan.&#xD;
&#xD;
          -  Has a current BMI-for-age (based on self-reported sex, age, height, and weight)&#xD;
             greater than or equal to 95th percentile for age and sex based on charts appropriate&#xD;
             locally for the country of residence.&#xD;
&#xD;
        Inclusion Criteria for Caregivers of Adolescents living with obesity:&#xD;
&#xD;
          -  Informed consent before any study-related activities (study-related activities are any&#xD;
             procedure related to recording of data according to the protocol).&#xD;
&#xD;
          -  Male or female, age above or equal to 24 years at the time of signing informed&#xD;
             consent.&#xD;
&#xD;
          -  Lives in one of the participating countries: Italy, Spain, UK, Mexico, Colombia,&#xD;
             Australia, Saudi Arabia, Turkey, South Korea, and Taiwan.&#xD;
&#xD;
          -  Has an adolescent in the household with a current BMI-for-age (based on self-reported&#xD;
             sex, age, height, and weight) greater than or equal to 95th percentile for age and sex&#xD;
             based on charts appropriate locally for the country of residence.&#xD;
&#xD;
          -  Resides in the same household as the ALwO at least 50% of the time.&#xD;
&#xD;
          -  Is involved in the healthcare decisions of the ALwO.&#xD;
&#xD;
        Inclusion Criteria for Health Care Providers:&#xD;
&#xD;
          -  Informed consent before any study-related activities (study-related activities are any&#xD;
             procedure related to recording of data according to the protocol).&#xD;
&#xD;
          -  Male or female, age above or equal to 18 years at the time of signing informed&#xD;
             consent.&#xD;
&#xD;
          -  Is a physician.&#xD;
&#xD;
          -  Practices in one of the participating countries: Italy, Spain, UK, Mexico, Colombia,&#xD;
             Australia, Saudi Arabia, Turkey, South Korea, and Taiwan&#xD;
&#xD;
          -  In clinical practice more than or equal to 2 years.&#xD;
&#xD;
          -  Spends at least 50% of time in direct patient care.&#xD;
&#xD;
          -  Has seen/treated at least ten adolescent patients (age 12 to less than 18 years) with&#xD;
             obesity in a typical month (defined as BMI-for-age greater than or equal to 95th&#xD;
             percentile for age and sex based on charts appropriate locally for the country of&#xD;
             residence).&#xD;
&#xD;
        Exclusion Criteria for Adolescents living with obesity:&#xD;
&#xD;
          -  Previous participation in this study. Participation is defined as having given&#xD;
             informed consent in this study.&#xD;
&#xD;
          -  Mental incapacity, unwillingness, inability, or language barriers precluding adequate&#xD;
             understanding or cooperation.&#xD;
&#xD;
          -  Has had significant weight loss or weight gain due to major injury or&#xD;
             illness/condition (e.g., cancer, accident, pregnancy) in the past 6 months.&#xD;
&#xD;
          -  Considers themselves to be extremely muscular.&#xD;
&#xD;
        Exclusion Criteria for Caregivers of Adolescents living with obesity:&#xD;
&#xD;
          -  Previous participation in this study. Participation is defined as having given&#xD;
             informed consent in this study.&#xD;
&#xD;
          -  Mental incapacity, unwillingness, inability, or language barriers precluding adequate&#xD;
             understanding or cooperation.&#xD;
&#xD;
          -  ALwO they care for has had significant weight loss or weight gain due to major injury&#xD;
             or illness/condition (e.g., cancer, accident, pregnancy) in the past 6 months.&#xD;
&#xD;
          -  Considers the ALwO they care for to be extremely muscular.&#xD;
&#xD;
        Exclusion Criteria for Health Care Providers:&#xD;
&#xD;
          -  Previous participation in this study. Participation is defined as having given&#xD;
             informed consent in this study.&#xD;
&#xD;
          -  Mental incapacity, unwillingness, inability, or language barriers precluding adequate&#xD;
             understanding or cooperation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sydney</city>
        <zip>NSW 2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bogot√°</city>
        <zip>110111</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>05510</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <zip>11560</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <zip>13315</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>106</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34335</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gatwick</city>
        <zip>RH6 0PA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Colombia</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Saudi Arabia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

